Navigation Links
Survival rates lower for heart transplant patients whose arteries reclose after stenting
Date:6/18/2012

Heart transplant patients are notorious for developing an aggressive form of coronary artery disease that can often result in heart failure, death or the need for repeat transplantation. The condition can also have a negative impact on future cardiac procedures, such as stenting.

Transplant patients are among those at highest risk of adverse outcomes when receiving a stent to address a blockage in an artery. Compared with the general public, these patients have a much higher rate of restenosis, a side effect of stenting in which the artery becomes re-blocked because of an exaggerated scarring process at the stenting site.

New research by UCLA researchers and colleagues has found that heart transplant patients who develop restenosis after receiving a stent have poor long-term survival. Their study, one of the largest and longest follow-up studies of this patient population, appeared in the June 15 edition of the American Journal of Cardiology.

"The findings point to the need for improvements in prevention and treatment of transplant coronary artery disease that may help reduce restenosis for patients who require later cardiac procedures like stenting," said Dr. Michael Lee, an assistant professor of cardiology at the David Geffen School of Medicine at UCLA.

A stenting procedure begins with an angioplasty, in which a catheter is placed in an artery of the groin and a tiny wire is snaked up through the artery to the blocked area of the heart. The clogged artery is cleaned out, and then a stent a tiny wire-mesh tube is passed up through the artery and deployed to keep the artery open, allowing blood to flow freely through the heart again.

Currently, there are no guidelines or treatment recommendations for in-stent restenosis for transplant coronary artery disease, Lee said. He suggests that a scoring system to help pinpoint risks might help identify good candidates for stenting and other catheter-based procedures.

For the study, Lee and his team followed 105 heart transplant patients who underwent a stent procedure at UCLA Medical Center between 1995 and 2009. Patients received either a bare metal stent or, in the later years of the study, a newer medication-coated stent that can help impede restenosis development.

The team found that patients at a seven-year follow-up who had not developed in-stent restenosis were further from an end-point of death, heart attack or repeat transplantation (63.2 percent) than patients who had developed restenosis (27.9 percent). This was primarily due to a lower survival rate in patients who developed restenosis (38.5 percent) compared to patients who did not (84.2 percent).

According to Lee, typically up to 50 percent of heart transplant patients who receive a medication-coated stent develop restenosis, compared with only 5 to 10 percent of the general population.

Researchers note that the exact mechanism that heightens the risk of death and heart attack and increases the need for additional transplant in patients with transplant coronary artery disease who develop in-stent restenosis is not known.

Lee added that organ rejection may contribute to transplant coronary disease and play a role in the increased risk of mortality. The development of blood clots in the arteries, known as intracoronary thrombus, may also contribute to mortality.

"We may find that development of restenosis in heart transplant patients may be a marker of a more aggressive inflammatory response and part of transplant rejection," Lee said.

Further studies will help better understand the role of other factors in developing transplant coronary artery disease and in-stent restenosis.


'/>"/>

Contact: Rachel Champeau
rchampeau@mednet.ucla.edu
310-794-2270
University of California - Los Angeles Health Sciences
Source:Eurekalert

Related medicine news :

1. Scientists discover mechanism that promotes lung cancer growth and survival
2. Haematopoietic stem cell transplantation increases survival in systemic sclerosis patients
3. Pre-op Treatments Boost Survival for Esophageal Cancer Patients: Study
4. ASCO: Younger colon cancer patients have worse prognosis at diagnosis, yet better survival
5. Fitness May Boost Survival for Women With Breast Cancer
6. Chemotherapys effect on overall survival seems to increase based on tumor size
7. Cancer vaccine combination therapy shows survival benefit in breast cancer
8. Living longer - variability in infection-fighting genes can be a boon for male survival
9. Exercise May Boost Survival in Breast, Colon Cancer Patients
10. UC Irvine study finds racial, economic disparities in ovarian cancer care, survival
11. Living Near Major Roads May Shorten Heart Attack Survival
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... ... notified by the Accreditation Council for Graduate Medical Education (ACGME) that it has ... This is the first accreditation of three residency programs that Memorial is currently ...
(Date:4/29/2016)... ... April 29, 2016 , ... Our bodies are bombarded daily by environmental and ... with these stressors is to adopt a more healthful diet, but too many people ... a certified Holistic Nutritionist and the creator of the Newport Beach Cleanse and 14-Day ...
(Date:4/29/2016)... ... April 29, 2016 , ... The ... nation’s productivity, stability, even security. Most importantly, employees are the single most important ... are American workers so unhappy? , Just under half of American workers are ...
(Date:4/29/2016)... ... April 29, 2016 , ... The ... in repaying their loans, more information about their loan terms and accounts, and ... student loan debt, including federal and private loans, has reached $1.3 trillion, with ...
(Date:4/29/2016)... ... ... Coast Dental Fort Stewart is celebrating its grand opening with an open ... Mall at 112 Vilseck Road in Fort Stewart. There will be refreshments, giveaways, and ... the opportunity to meet general dentists Thomas Richards, DDS, and Josh Faulk, DMD, and ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)...   Acsis , a leading provider of supply ... research and advisory firm IDC has named it a ... Pharmaceutical Track and Trace Software 2016 Vendor Assessment (doc ... of the capabilities and business strategies of 10 vendors ... Logo - http://photos.prnewswire.com/prnh/20160427/360791LOGO ...
(Date:4/28/2016)... , April 28, 2016 ... development of innovative peptide and gene-based immunotherapeutics and vaccines for ... will be presenting at the 3rd Annual Growth Capital ... 5 th , 2016 at Caesars Palace in Las Vegas, Nevada.  ... am on Wednesday, May 4 th by Dr. ...
(Date:4/27/2016)... -- Hologic, Inc. (Nasdaq: HOLX ) announced ... second quarter ended March 26, 2016.  GAAP diluted ... and non-GAAP diluted EPS of $0.47 increased 14.6%.  ... reported basis, and 6.3% on a constant currency ... quarter, highlighted by 14.6% growth in non-GAAP EPS," ...
Breaking Medicine Technology: